ModifiedCapital BluecrossPolicy MP 1.145

Magnetic esophageal sphincter augmentation to treat gastroesophageal reflux disease

This policy governs coverage for magnetic esophageal sphincter augmentation (LINX Reflux Management System) to treat gastroesophageal reflux disease for members of certain Capital Blue Cross programs.

Policy Summary

PayerCapital Bluecross

PolicyMagnetic esophageal sphincter augmentation to treat gastroesophageal reflux disease

Policy CodePolicy MP 1.145

Change TypeReactivated as investigationaladministrative clarifications

Effective Date8/1/2025

Next Review Date

Key ActionDo not expect prior authorization to make the investigational procedure eligible for coverage; verify member benefits and eligibility.

SourceLink

POLICY UPDATE CHANGES

Policy reactivated and magnetic sphincter augmentation is investigational.

Administrative update removed Benefit Variations section and updated Disclaimer.

2Procedure codes investigational / not covered

InsufficientOverall evidence conclusion

02/04/2025Policy reactivation date

06/24/2025Administrative update date

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

≥1 RCTRCTs summarized

Coverage Determination

Overall coverage stance

Covered only when supported by evidence; current policy statement:

Policy stance: Magnetic esophageal sphincter augmentation to treat gastroesophageal reflux disease is investigational.

There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure; randomized comparisons to fundoplication are needed.

Investigational / Not covered

Covered when ALL of the following are met

Policy stance: Magnetic sphincter augmentation is investigational

Policy MP 1.145 was reactivated as investigational on 02/04/2025; services are not covered as investigational per this policy.

Procedures reported with CPT codes 43284 and 43285 are designated investigational and are not covered under this policy.

Magnetic sphincter augmentation is designated investigational, which implies these services are excluded from coverage as not medically necessary under this policy. The policy was reactivated on 02/04/2025 confirming the investigational designation.

Use of magnetic esophageal sphincter augmentation (MSA) is considered investigational; the evidence is insufficient to determine that MSA improves net health outcome compared with alternative treatments.

Magnetic sphincter augmentation is classified as investigational by this policy. Because the evidence does not establish clinical benefit, MSA is not covered.

Coding and Billing

Investigational; therefore, not covered: Procedure CodesCPTNot Covered

43284	Procedure code listed in policy as investigational; therefore not covered
43285	Procedure code listed in policy as investigational; therefore not covered

Provider Actions and Administrative Notes

Denial Risk

Investigational procedure — Coverage status

Magnetic esophageal sphincter augmentation (LINX) is designated investigational and is not a covered benefit. Prior authorization alone does not make investigational services eligible for coverage; claims for this procedure may be denied as not medically necessary or investigational.

Investigational — prior authorization not sufficient for coverage
Procedure classified investigational; claims may be denied

Prior Authorization

Benefit / program verification required

Verify member benefits and program applicability before authorization or scheduling. Coverage depends on the member's specific benefit program and eligibility on the date of service. Administrative updates may change program applicability (e.g., removal of Benefit Variations section).

Benefit/program verification required — confirm member coverage and program details

Background and Rationale

Gastroesophageal reflux disease (GERD) is the backflow of stomach contents into the esophagus and affects an estimated 10–20% of people in developed countries. The LINX magnetic sphincter augmentation system is a laparoscopically implanted ring of magnetic beads intended to augment the lower esophageal sphincter for patients with GERD who have persistent symptoms despite medical therapy. This policy (MP 1.145) was reactivated on 02/04/2025 and currently designates magnetic sphincter augmentation as investigational.

Definitions

Gastroesophageal reflux disease (GERD) — definition and clinical features

DefinitionGastroesophageal reflux disease (GERD) — backflow of stomach contents into the esophagus often due to incompetence of the lower esophageal sphincter.

PathophysiologyGastric juices are acidic and can produce burning pain in the esophagus; repeated reflux may cause esophagitis, peptic esophageal stricture, or esophageal ulcer.

Clinical presentationSymptoms commonly include heartburn and regurgitation; complications may include esophagitis, strictures, or ulcers from chronic exposure to gastric acid.

First-line management contextStandard medical therapy (e.g., proton pump inhibitors) is considered first-line treatment for GERD symptoms before procedural interventions.

Magnetic sphincter augmentation — device definition and intended use

Device name

Policy Summary

PayerCapital Bluecross

PolicyMagnetic esophageal sphincter augmentation to treat gastroesophageal reflux disease

Policy CodePolicy MP 1.145

Change TypeReactivated as investigationaladministrative clarifications

Effective Date8/1/2025

Next Review Date

Key ActionDo not expect prior authorization to make the investigational procedure eligible for coverage; verify member benefits and eligibility.

SourceLink

On This Page

Administrative note: Benefit Variations section was removed (06/24/2025)

Billing Rule

Billing / denial risk — affected codes

If submitting claims, expect denial for investigational services. The following CPT/Procedure codes are identified with investigational status and are subject to denial when billed for magnetic sphincter augmentation.

Procedure codes: 43284, 43285 — investigational / not covered

Note

Clinical context — medical therapy

Standard medical therapy (e.g., proton pump inhibitors) is first-line; magnetic sphincter augmentation is intended for patients with persistent symptoms despite maximal medical therapy but remains investigational per this policy.

Medical therapy prerequisite (context) — LINX proposed for persistent symptoms despite medical therapy

Documentation Required

PROVIDER ACTIONS

Provider action: do not assume prior authorization guarantees coverage. Because the procedure is classified investigational, do not schedule or perform expecting payment without confirmed benefit coverage and explicit authorization that recognizes investigational exceptions, if any.

Procedure is investigational — do not rely on prior authorization alone for coverage determination
Confirm benefit eligibility and obtain explicit payer confirmation if an exception is sought

Magnetic sphincter augmentation (commonly the LINX Reflux Management System)

Intended useA laparoscopically implanted device composed of magnetic beads to augment the lower esophageal sphincter for management of GERD in patients with persistent symptoms despite medical therapy.

Clinical roleIntended to restore barrier function of the lower esophageal sphincter and reduce reflux; discussed in society statements and clinical guidelines referenced by the policy.

Evidence contextEvaluated in randomized and observational studies and addressed in multi-society guidelines and consensus statements cited in the policy references.